Você pesquisou por y - Revista Brasileira de Ginecologia e Obstetrícia
You searched for:"Sebastião Freitas de Medeiros"
We found (21) results for your search.
, , , , , Summary
Revista Brasileira de Ginecologia e Obstetrícia. 2024;46:e-FPS11
, , , , , , , , , 
Summary
Revista Brasileira de Ginecologia e Obstetrícia. 2024;46:e-FPS11
, , , , , , , , , 
, , , , Summary
Revista Brasileira de Ginecologia e Obstetrícia. 2022;44(2):142-153
, , , , To examine the possible effects of adrenal prohormones in the prediction of clinical and metabolic abnormalities in women with polycystic ovary syndrome (PCOS).
The present study enrolled 299 normal cycling non-PCOS, 156 normoandrogenemic, and 474 hyperandrogenemic women with PCOS. Baseline characteristics were compared using a chi-squared test or analysis of variance (ANOVA) as appropriate. The roles of adrenal prohormones and their ratios with total testosterone in predicting co-occurring morbidities in women PCOS were evaluated using univariate and multivariate logistic regression analyses.
Adrenal hyperandrogenism per dehydroepiandrosterone sulfate (DHEAS) levels were found in 32% of women with PCOS. In non-PCOS women, dehydroepiandrosterone (DHEA) and its sulfate had no predictive role concerning clinical, anthropometric, and metabolic parameters. In PCOS women, mainly in the hyperandrogenemic group, DHEA showed to be a significant predictor against most anthropometric-metabolic index abnormalities (odds ratio [OR]=0.36-0.97; p<0.05), and an increase in triglycerides (TG) levels (OR=0.76; p=0.006). Dehydroepiandrosterone sulfate presented a few predictive effects regarding PCOS-associated disorders. In controls, DHEAS predicted against the increase in estimated average glucose (OR= 0.38; p=0.036). In the normoandrogenic group, it predicted against elevation in the waist/hip ratio (WHR) (OR= 0.59; p=0.042), and in hyperandrogenemic PCOS women, it predicted against abnormality in the conicity index (CI) (OR=0.31; p=0.028).
Dehydroepiandrosterone was shown to be a better predictor of abnormal anthropometric and biochemical parameters in women with PCOS than DHEAS. Thus, regarding adrenal prohormones, DHEA measurement, instead of DHEAS, should be preferred in PCOS management. The effects of androgen prohormones on the prediction of PCOS abnormalities are weak.
Summary
Revista Brasileira de Ginecologia e Obstetrícia. 2022;44(2):142-153
, , , , To examine the possible effects of adrenal prohormones in the prediction of clinical and metabolic abnormalities in women with polycystic ovary syndrome (PCOS).
The present study enrolled 299 normal cycling non-PCOS, 156 normoandrogenemic, and 474 hyperandrogenemic women with PCOS. Baseline characteristics were compared using a chi-squared test or analysis of variance (ANOVA) as appropriate. The roles of adrenal prohormones and their ratios with total testosterone in predicting co-occurring morbidities in women PCOS were evaluated using univariate and multivariate logistic regression analyses.
Adrenal hyperandrogenism per dehydroepiandrosterone sulfate (DHEAS) levels were found in 32% of women with PCOS. In non-PCOS women, dehydroepiandrosterone (DHEA) and its sulfate had no predictive role concerning clinical, anthropometric, and metabolic parameters. In PCOS women, mainly in the hyperandrogenemic group, DHEA showed to be a significant predictor against most anthropometric-metabolic index abnormalities (odds ratio [OR]=0.36-0.97; p<0.05), and an increase in triglycerides (TG) levels (OR=0.76; p=0.006). Dehydroepiandrosterone sulfate presented a few predictive effects regarding PCOS-associated disorders. In controls, DHEAS predicted against the increase in estimated average glucose (OR= 0.38; p=0.036). In the normoandrogenic group, it predicted against elevation in the waist/hip ratio (WHR) (OR= 0.59; p=0.042), and in hyperandrogenemic PCOS women, it predicted against abnormality in the conicity index (CI) (OR=0.31; p=0.028).
Dehydroepiandrosterone was shown to be a better predictor of abnormal anthropometric and biochemical parameters in women with PCOS than DHEAS. Thus, regarding adrenal prohormones, DHEA measurement, instead of DHEAS, should be preferred in PCOS management. The effects of androgen prohormones on the prediction of PCOS abnormalities are weak.
Summary
Revista Brasileira de Ginecologia e Obstetrícia. 2021;43(7):578-578
Summary
Revista Brasileira de Ginecologia e Obstetrícia. 2021;43(7):578-578
, , , Summary
Revista Brasileira de Ginecologia e Obstetrícia. 2021;43(6):480-486
, , , The process of ovulation involves multiple and iterrelated genetic, biochemical, and morphological events: cessation of the proliferation of granulosa cells, resumption of oocyte meiosis, expansion of cumulus cell-oocyte complexes, digestion of the follicle wall, and extrusion of the metaphase-II oocyte. The present narrative review examines these interrelated steps in detail. The combined or isolated roles of the folliclestimulating hormone (FSH) and luteinizing hormone (LH) are highlighted. Genes indiced by the FSH genes are relevant in the cumulus expansion, and LH-induced genes are critical for the resumption ofmeiosis and digestion of the follicle wall. A nonhuman model for follicle-wall digestion and oocyte release was provided.
Summary
Revista Brasileira de Ginecologia e Obstetrícia. 2021;43(6):480-486
, , , The process of ovulation involves multiple and iterrelated genetic, biochemical, and morphological events: cessation of the proliferation of granulosa cells, resumption of oocyte meiosis, expansion of cumulus cell-oocyte complexes, digestion of the follicle wall, and extrusion of the metaphase-II oocyte. The present narrative review examines these interrelated steps in detail. The combined or isolated roles of the folliclestimulating hormone (FSH) and luteinizing hormone (LH) are highlighted. Genes indiced by the FSH genes are relevant in the cumulus expansion, and LH-induced genes are critical for the resumption ofmeiosis and digestion of the follicle wall. A nonhuman model for follicle-wall digestion and oocyte release was provided.
Summary
Revista Brasileira de Ginecologia e Obstetrícia. 2020;42(1):26-34
To assess the construct and criterion validity of the Postmenopause Sexuality Questionnaire (PMSQ).
The present methodological questionnaire validation study included postmenopausal women. The construct validity was tested by factor analysis and the criterion validity was performed using the correlation between the PMSQ and the Female Sexual Function Index (FSFI). The ROC curve was used to verify sensitivity, specificity and to determine the cutoff point of the PMSQ.
A total of 181 women with amean age of 56.4 ± 5.7 years old were evaluated. The exploratory factor analysis showed that the PMSQ presented Kaiser test = 0.88 and χ2 = 3293.7 (p < 0.001), commonalities ≥ 0.5, and extraction of 9 factors with eigenvalue ≥ 1; explaining 66.3% of the total variance. The PMSQ presented factor loadings between 0.4 and 0.8. A strong correlation between the 2 questionnaires (r = 0.79; p = 0.000) was shown. The cutoff point of the PMSQ was ≤ 55.5, assuming 87.9% sensitivity and 78.9% specificity (p < 0.001).
Since the PMSQ showed a strong correlation with the FSFI questionnaire, it presented good psychometric properties to assess the sexuality in postmenopausal women. Based on these results, the PMSQ could be widely tested as a specific instrument to examine the sexual function in postmenopausal women. Future studies, designed to examine the PMSQ instrument in different populations, are needed.
Summary
Revista Brasileira de Ginecologia e Obstetrícia. 2020;42(1):26-34
To assess the construct and criterion validity of the Postmenopause Sexuality Questionnaire (PMSQ).
The present methodological questionnaire validation study included postmenopausal women. The construct validity was tested by factor analysis and the criterion validity was performed using the correlation between the PMSQ and the Female Sexual Function Index (FSFI). The ROC curve was used to verify sensitivity, specificity and to determine the cutoff point of the PMSQ.
A total of 181 women with amean age of 56.4 ± 5.7 years old were evaluated. The exploratory factor analysis showed that the PMSQ presented Kaiser test = 0.88 and χ2 = 3293.7 (p < 0.001), commonalities ≥ 0.5, and extraction of 9 factors with eigenvalue ≥ 1; explaining 66.3% of the total variance. The PMSQ presented factor loadings between 0.4 and 0.8. A strong correlation between the 2 questionnaires (r = 0.79; p = 0.000) was shown. The cutoff point of the PMSQ was ≤ 55.5, assuming 87.9% sensitivity and 78.9% specificity (p < 0.001).
Since the PMSQ showed a strong correlation with the FSFI questionnaire, it presented good psychometric properties to assess the sexuality in postmenopausal women. Based on these results, the PMSQ could be widely tested as a specific instrument to examine the sexual function in postmenopausal women. Future studies, designed to examine the PMSQ instrument in different populations, are needed.
, Summary
Revista Brasileira de Ginecologia e Obstetrícia. 2019;41(3):183-190
, Considering that myths and misconceptions regarding natural procreation spread rapidly in the era of easy access to information and to social networks, adequate counseling about natural fertility and spontaneous conception should be encouraged in any kind of health assistance. Despite the fact that there is no strong-powered evidence about any of the aspects related to natural fertility, literature on how to increase the chances of a spontaneous pregnancy is available. In the present article, the Brazilian Federation of Gynecology and Obstetrics Associations (FEBRASGO, in the Portuguese acronym) Committee on Endocrine Gynecology provides suggestions to optimize counseling for non-infertile people attempting spontaneous conception.
Summary
Revista Brasileira de Ginecologia e Obstetrícia. 2019;41(3):183-190
, Considering that myths and misconceptions regarding natural procreation spread rapidly in the era of easy access to information and to social networks, adequate counseling about natural fertility and spontaneous conception should be encouraged in any kind of health assistance. Despite the fact that there is no strong-powered evidence about any of the aspects related to natural fertility, literature on how to increase the chances of a spontaneous pregnancy is available. In the present article, the Brazilian Federation of Gynecology and Obstetrics Associations (FEBRASGO, in the Portuguese acronym) Committee on Endocrine Gynecology provides suggestions to optimize counseling for non-infertile people attempting spontaneous conception.
Summary
Revista Brasileira de Ginecologia e Obstetrícia. 2018;40(5):275-280
Gender incongruence is defined as a condition in which an individual self-identifies and desires to have physical characteristics and social roles that connote the opposite biological sex. Gender dysphoria is when an individual displays the anxiety and/or depression disorders that result from the incongruity between the gender identity and the biological sex. The gender affirmation process must be performed by a multidisciplinary team. The main goal of the hormone treatment is to start the development of male physical characteristics by means of testosterone administration that may be offered to transgender men who are 18 years old or over. The use of testosterone is usually well tolerated and improves the quality of life. However, there is still lack of evidence regarding the effects and risks of the long-term use of this hormone. Many different pharmacological formulations have been used in the transsexualization process. The most commonly used formulation is the intramuscular testosterone esters in a short-term release injection, followed by testosterone cypionate or testosterone enanthate. In the majority of testosterone therapy protocols, the male physical characteristics can be seen in almost all users after 6 months of therapy, and themaximum virilization effects are usually achieved after 3 to 5 years of regular use of the hormone. To minimize risks, plasmatic testosterone levels should be kept within male physiological ranges (300 to 1,000 ng/dl) during hormonal treatment. It is recommended that transgender men under androgen therapy be monitored every 3 months during the 1st year of treatment and then, every 6 to 12 months.
Summary
Revista Brasileira de Ginecologia e Obstetrícia. 2018;40(5):275-280
Gender incongruence is defined as a condition in which an individual self-identifies and desires to have physical characteristics and social roles that connote the opposite biological sex. Gender dysphoria is when an individual displays the anxiety and/or depression disorders that result from the incongruity between the gender identity and the biological sex. The gender affirmation process must be performed by a multidisciplinary team. The main goal of the hormone treatment is to start the development of male physical characteristics by means of testosterone administration that may be offered to transgender men who are 18 years old or over. The use of testosterone is usually well tolerated and improves the quality of life. However, there is still lack of evidence regarding the effects and risks of the long-term use of this hormone. Many different pharmacological formulations have been used in the transsexualization process. The most commonly used formulation is the intramuscular testosterone esters in a short-term release injection, followed by testosterone cypionate or testosterone enanthate. In the majority of testosterone therapy protocols, the male physical characteristics can be seen in almost all users after 6 months of therapy, and themaximum virilization effects are usually achieved after 3 to 5 years of regular use of the hormone. To minimize risks, plasmatic testosterone levels should be kept within male physiological ranges (300 to 1,000 ng/dl) during hormonal treatment. It is recommended that transgender men under androgen therapy be monitored every 3 months during the 1st year of treatment and then, every 6 to 12 months.